Single dose inhaler that addresses new and existing needs.
| Reference number | |
| Coordinator | Iconovo AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | December 2013 - June 2014 |
| Status | Completed |
Important results from the project
The project is to develop and promote a dry powder inhalation device for drug delivery to the lung. The device is a unit-dose disposable inhaler. The inhaler is intended for vaccines, treatment of non-chronic diseases where only a few doses are to administered, expensive drugs where waste should be minimized, acute treatment, clinical trials etc. A market study of the inhalation market with specific focus on dry powder products and single dose inhalers has been carried out together with a patent assessment. Initial concepts have been developed to a prototype stage.
Expected long term effects
The market study showed a growing need for dry powder inhalation devices. Many global drug products will become off-paten in 2014 driving a demand for inhalation devices. Many new indications for inhaled drug deliver were identified e.g. diabetes, vaccines and cystic fibrosis. Also biomolecules are seen as suitable for single dose inhalers. The market study confirmed and quantified Iconovo´s business model and will be very helpful in the financing of the company
Approach and implementation
A market study of the inhalation market with specific focus on dry powder products and single dose inhalers has been carried out. in parallel a patent investigation was made to support the concept development. A concept was developed to a prototype stage and a patent application was filed